


HEALTHCARE

Pharmaceutical Growth Opportunities in Brazil, Russia, India and China

Healthcare reform, market dynamics and key players

By Revati Nehru

 [Table of Contents](#)

Revati Nehru

Revati Nehru is a healthcare analyst, with several years experience in healthcare marketing and market analysis across therapeutic areas such as cancer and cardiovascular. During this time she has worked for multinational pharmaceutical companies and independent research houses.

Copyright © 2006 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Pharmaceutical Growth Opportunities in Brazil, Russia, India and China

Executive Summary	12	
The external environment in the BRIC markets	12	
The market opportunity in the BRIC countries	13	
Market composition in the BRIC countries	14	
Competitive dynamics in the BRIC region	15	
Key players and winning strategies	16	
Chapter 1	The external environment in the BRIC markets	18
Summary		18
Introduction		19
Background		20
Healthcare systems and structures across the BRIC markets		21
Healthcare financing		21
Pharmaceutical expenditure in the context of healthcare spends		25
Private and public sources of healthcare financing		27
Epidemiological analysis		29
Major disease states		30
Structural challenges to pharmaceutical marketers in the BRIC countries		34
Healthcare delivery		35
Social aspects		35
Market factors		35
Pricing and reimbursement		36
Healthcare reform in the BRIC countries		38
Profiles of healthcare systems across the BRIC countries		40
Brazil		41
Healthcare system		41
Healthcare financing and expenditure		47
Pricing and reimbursement		48

	Political and regulatory issues	49
Russia		51
	Healthcare system	51
	Healthcare financing and expenditure	56
	Pricing and reimbursement	57
	Political and regulatory issues	58
India		59
	Healthcare system	59
	Healthcare financing and expenditure	63
	Pricing and reimbursement	65
	Political and regulatory issues	66
China		67
	Healthcare system	67
	Healthcare financing and expenditure	71
	Pricing and reimbursement	73
	Political and regulatory issues	74

Chapter 2 The market opportunity in the BRIC countries 78

Summary	78
Introduction	79
BRIC market dynamics	80
Comparative dynamics between the BRIC markets and the global market	81
Market composition by therapeutic areas	84
Market analysis by therapeutic area	87
Cardiovascular market analysis	87
CNS disorders market analysis	92
Cancer market analysis	98
Respiratory market analysis	102
Anti-infectives market analysis	106
Minor therapeutic areas analysis	112
Forecast sales by therapy area	113

Chapter 3 Market composition in the BRIC countries 118

Summary	118
Introduction	119
Licensing trends: a comparison with the global market	119
Market breakdown by country	123
Brazil	124
Russia	125

India	125
China	126
Therapeutic licensing trends in the BRIC countries	128
Cardiovascular	129
CNS disorders	130
Cancer	132
Anti-infectives	133
Respiratory	135
Other therapeutic areas	136
Current and future potential	139

Chapter 4 Competitive dynamics in the BRIC region 144

Summary	144
Introduction	145
Competitive dynamics in each BRIC market	146
Brazil	148
Russia	151
India	153
China	155

Chapter 5 Key players and winning strategies 158

Summary	158
Key players in the BRIC markets	159
Key multinational players	159
Sanofi-Aventis	159
Novartis	163
Pfizer	167
GlaxoSmithKline	171
Key medium-sized international players	175
Gedeon Richter	175
Servier	180
Menarini	184
Key Brazilian regional players	188
Aché Laboratórios Farmacêuticos	188
EMS	192
Medley	195
Key Indian regional players	198
Cipla	198
Nicholas Piramal	203
Ranbaxy	208

Key Chinese regional players	214
HLJ. Harbin	214
Jiang Su Hengrui Medicine	217
Yangzijiang/Yangtze River Group	221
Winning strategies in the BRIC markets	225
Competitive strategy of key multinational players in the BRIC markets	227
Competitive strategy of key medium-sized players in the BRIC markets	229
Competitive strategy of regional pharmaceutical players in the BRIC markets	230
Brazil	230
India	232
China	233

Chapter 6 Appendix 236

IMS sales data	236
Glossary	237
Index	240

List of Figures

Figure 1.1:	Comparison of pharmaceutical sales in the markets of BRIC, EU5, US and Japan, 2005	20
Figure 1.2:	Average total health expenditure as a proportion of GDP for BRIC, EU5 and the US, 2000-04	22
Figure 1.3:	Healthcare expenditures across the four BRIC countries, 2004	23
Figure 1.4:	Comparison of spends on pharmaceuticals between the US, 5 major EU markets and the BRIC markets, 2004	25
Figure 1.5:	Private healthcare expenditure as a percentage of total healthcare expenditure in the BRIC countries, 2004	27
Figure 1.6:	Structural challenges to pharmaceutical marketers in the BRIC countries	34
Figure 1.7:	Major challenges in healthcare reform in the BRIC countries	39
Figure 1.8:	Average total health expenditure as % of GDP for Brazil and the BRIC economies, 2000-04	43
Figure 1.9:	Summary structure of Brazilian healthcare system	46
Figure 1.10:	Summary structure of the Russian healthcare system	53
Figure 1.11:	Average total health expenditure as % of GDP for Russia and the BRIC economies, 2000-04	54
Figure 1.12:	Summary structure of the Indian healthcare system	60
Figure 1.13:	Average total health expenditure as % of GDP for India and the BRIC economies, 2000-04	62
Figure 1.14:	Summary structure of Chinese healthcare system	68
Figure 1.15:	Average total health expenditure as % of GDP for China and the BRIC economies, 2000-04	70
Figure 1.16:	Average private health expenditure for China, 2000-04	72
Figure 2.17:	Cardiovascular market breakdown by therapy area sales for individual markets of BRIC, 2001-2005	92
Figure 2.18:	CNS market breakdown by therapy area sales for individual markets of BRIC, 2001-2005	97
Figure 2.19:	Cancer market breakdown by therapy area sales for individual markets of BRIC, 2001-2005	101
Figure 2.20:	Respiratory market breakdown by therapy area sales for individual markets of BRIC, 2001-2005	105
Figure 2.21:	Anti-infectives market breakdown by therapy area sales for individual markets of BRIC, 2001-2005	111
Figure 3.22:	Comparison of sales in the global and BRIC markets by product category, 2005	122
Figure 3.23:	Comparison of sales in the BRIC market by product category, 2005	127
Figure 3.24:	Penetration of original brands across therapy areas in the BRIC markets, 2005	140
Figure 3.25:	Forecast prospects for market development of major categories of brands by indication, 2006-11	141
Figure 4.26:	Breakdown of the leading pharmaceutical companies in the BRIC markets, 2005	145
Figure 4.27:	Growth dynamics of the leading pharmaceutical companies in Brazil, 2005	150
Figure 4.28:	Growth dynamics of the leading pharmaceutical companies in Russia, 2005	152
Figure 4.29:	Growth dynamics of the leading pharmaceutical companies in India, 2005	154
Figure 4.30:	Growth dynamics of leading pharmaceutical companies in China, 2005	156
Figure 5.31:	Presence of multinational pharmaceutical players in the BRIC market, 2005	227
Figure 5.32:	Presence of medium-sized international pharmaceutical players in the BRIC market, 2005	229

Figure 5.33:	Presence of domestic Brazilian pharmaceutical players in the BRIC market, 2005	231
Figure 5.34:	Presence of domestic Indian pharmaceutical players in the BRIC market, 2005	232
Figure 5.35:	Presence of domestic Chinese pharmaceutical players in the BRIC market, 2005	234

List of Tables

Table 1.1:	Recent statistics on healthcare sector in the BRIC markets, 2004	24
Table 1.2:	Comparison of spends on pharmaceuticals between the US, 5 major EU markets and the BRIC markets, 2004	26
Table 1.3:	Public and private healthcare financing in the BRIC markets, 2004	28
Table 1.4:	Prevalence rates of cardiovascular diseases among the 4 BRIC markets, 2004	30
Table 1.5:	Incidence rates* of cancer among the 4 BRIC markets, 2004	31
Table 1.6:	Summary of pricing and reimbursement policies across the BRIC markets, 2004	37
Table 1.7:	Number of healthcare facilities in Brazil by type of care and type of holding facility, 1980-2002	44
Table 1.8:	Health system expenditure & financing in Brazil, 2000-04	47
Table 1.9:	Healthcare facility statistics for Russia, 2000-04	55
Table 1.10:	Health system expenditure & financing in Russia, 2000-04	56
Table 1.11:	Health system expenditure & financing in India, 2000-04	63
Table 1.12:	Health system expenditure & financing in China, 2000-04	71
Table 2.13:	Pharmaceutical market dynamics across the BRIC countries, 2004-05	80
Table 2.14:	Breakdown of sales by major therapeutic area across the combined BRIC market, 2004-05	81
Table 2.15:	Breakdown of sales by major therapeutic area across the global market, 2004-05	82
Table 2.16:	Breakdown of sales by therapeutic area across the BRIC and the global markets, 2005	84
Table 2.17:	Sales by major classes across the BRIC cardiovascular market, 2004-05	87
Table 2.18:	Cardiovascular sales in the BRIC markets by indication and country, 2004-05	90
Table 2.19:	Sales by major classes across the BRIC CNS market, 2004-05	93
Table 2.20:	CNS sales in the BRIC markets by indication and country, 2004-05	95
Table 2.21:	Sales by major classes across the BRIC cancer market, 2004-2005	98
Table 2.22:	Cancer sales in the BRIC markets by indication and country, 2004-05	99
Table 2.23:	Sales by major classes across the BRIC respiratory market, 2004-05	102
Table 2.24:	Respiratory sales in the BRIC markets by indication and country, 2004-05	103
Table 2.25:	Sales by major classes across the BRIC anti-infectives market, 2004-05	106
Table 2.26:	Anti-infectives sales in the BRIC markets by indication and country, 2004-2005	108
Table 2.27:	Sales of other therapeutic categories in the BRIC markets,	112
Table 2.28:	Forecast sales by therapeutic area across the BRIC markets, 2005-11	114
Table 3.29:	Sales in the BRIC countries and global pharmaceutical markets by product category, 2004-05	120
Table 3.30:	Sales in the BRIC pharmaceutical markets by category, 2004-05	123
Table 3.31:	Therapeutic sales in the BRIC pharmaceutical markets by product category, 2005	128
Table 3.32:	Sales of cardiovascular therapeutics in the BRIC markets by product category, 2005	129
Table 3.33:	Sales of CNS therapeutics in the BRIC markets by product category, 2005	130
Table 3.34:	Sales of cancer therapies in the BRIC markets by product category, 2005	132
Table 3.35:	Sales of anti-infectives in the BRIC markets by product category, 2005	133
Table 3.36:	Sales of respiratory in the BRIC markets by product category, 2005	135
Table 3.37:	Licensing trends in other therapeutic areas of the BRIC markets, 2005	136

Table 4.38:	Sales of leading companies in the BRIC markets, 2004-05	147
Table 4.39:	Sales of leading pharmaceutical companies in Brazil, 2004-05	149
Table 4.40:	Sales of leading pharmaceutical companies in Russia, 2004-05	151
Table 4.41:	Sales of leading pharmaceutical companies in India, 2004-05	153
Table 4.42:	Sales of leading pharmaceutical companies in China, 2004-05	155
Table 5.43:	Sanofi-Aventis' sales by country in the BRIC pharmaceutical markets, 2004-05	160
Table 5.44:	Sanofi-Aventis' portfolio sales in the BRIC pharmaceutical markets, 2004-05	161
Table 5.45:	Novartis' sales by country in the BRIC pharmaceutical markets, 2004-05	164
Table 5.46:	Novartis' portfolio sales in the BRIC pharmaceutical markets, 2004-05	165
Table 5.47:	Pfizer's sales by country in the BRIC pharmaceutical markets, 2004-05	167
Table 5.48:	Pfizer's portfolio sales in the BRIC pharmaceutical markets, 2004-05	168
Table 5.49:	GSK's sales by country in the BRIC pharmaceutical markets, 2004-05	171
Table 5.50:	GSK's portfolio sales in the BRIC pharmaceutical markets, 2004-05	172
Table 5.51:	Gedeon Richter's sales by country in the BRIC pharmaceutical markets, 2004-05	176
Table 5.52:	Gedeon Richter's portfolio sales in the BRIC pharmaceutical markets, 2004-05	176
Table 5.53:	Gedeon Richter's corporate agreements, 2000-2006	178
Table 5.54:	Servier's sales by country in the BRIC pharmaceutical markets, 2004-05	180
Table 5.55:	Servier's portfolio sales in the BRIC pharmaceutical markets, 2004-05	181
Table 5.56:	Servier's corporate agreements, 2000-2006	183
Table 5.57:	Menarini's sales by country in the BRIC pharmaceutical markets, 2004-05	184
Table 5.58:	Menarini's portfolio sales in the BRIC pharmaceutical markets, 2004-05	185
Table 5.59:	Menarini's corporate agreements, 2000-2006	186
Table 5.60:	Aché's sales by country in the BRIC pharmaceutical markets, 2004-05	188
Table 5.61:	Aché's portfolio sales in the BRIC pharmaceutical markets, 2004-05	189
Table 5.62:	Aché's corporate agreements, 2000-2006	191
Table 5.63:	EMS' sales by country in the BRIC pharmaceutical markets, 2004-05	192
Table 5.64:	EMS's portfolio sales in the BRIC pharmaceutical markets, 2004-05	193
Table 5.65:	EMS's corporate agreements, 2000-2006	194
Table 5.66:	Medley's sales by country in the BRIC pharmaceutical markets, 2004-05	195
Table 5.67:	Medley's portfolio sales in the BRIC pharmaceutical markets, 2004-05	196
Table 5.68:	Medley's corporate agreements, 2000-2006	197
Table 5.69:	Cipla's sales by country in the BRIC pharmaceutical markets, 2004-05	198
Table 5.70:	Cipla's portfolio sales in the BRIC pharmaceutical markets, 2004-05	199
Table 5.71:	Cipla's corporate agreements, 2000-2006	202
Table 5.72:	Nicholas Piramal's sales by country in the BRIC pharmaceutical markets, 2004-05	203
Table 5.73:	Nicholas Piramal's portfolio sales in the BRIC pharmaceutical markets, 2004-05	204
Table 5.74:	Nicholas Piramal's corporate agreements, 2000-2006	207
Table 5.75:	Ranbaxy's sales by country in the BRIC pharmaceutical markets, 2004-05	209
Table 5.76:	Ranbaxy's portfolio sales in the BRIC pharmaceutical markets, 2004-05	210
Table 5.77:	Ranbaxy's corporate agreements, 2000-2006	213
Table 5.78:	HLJ. Harbin's sales by country in the BRIC pharmaceutical markets, 2004-05	215
Table 5.79:	HLJ. Harbin's portfolio sales in the BRIC pharmaceutical markets, 2004-05	216
Table 5.80:	JS.Hengrui's sales by country in the BRIC pharmaceutical markets, 2004-05	217
Table 5.81:	JS.Hengrui's portfolio sales in the BRIC pharmaceutical markets, 2004-05	218
Table 5.82:	JS. Hengrui's corporate agreements, 2000-2006	220
Table 5.83:	Yangtze's sales by country in the BRIC pharmaceutical markets, 2004-05	221
Table 5.84:	Yangtze portfolio sales in the BRIC pharmaceutical markets, 2004-05	222
Table 5.85:	Yangtze's corporate agreements, 2000-2006	224